Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

2018374 citationsJournal Articlehybrid Open Access

Authors

Neal Ready · Duke Medical Center

Anna F. Farago · Massachusetts General Hospital

Filippo de Braud · University of Milan

Akin Atmaca · Krankenhaus Nordwest

Matthew D. Hellmann · Memorial Sloan Kettering Cancer Center

Jeffrey Schneider · Winthrop-University Hospital

David R. Spigel

Abstract

Nivolumab monotherapy provided durable responses and was well tolerated as a third- or later-line treatment for recurrent SCLC. These results suggest that nivolumab monotherapy is an effective third- or later-line treatment for this patient population.

Topics & Keywords

Lung Cancer Research Studies Neuroendocrine Tumor Research Advances Pancreatic and Hepatic Oncology Research

Publication Details

Published in: Journal of Thoracic Oncology

Volume 14, Issue 2, pp. 237-244

DOI: 10.1016/j.jtho.2018.10.003

Field-Weighted Citation Impact: 18.69

Command Palette

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Authors

Abstract

Topics & Keywords

Publication Details